Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

Abbott’s industry partners seem to view these collaborations ... Abbott’s FreeStyle Libre products have more than six million users who have type 1 or type 2 diabetes. She added that the ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device ...

So, while you should always follow the fundamentals of healthy living – like exercising and eating a balanced diet – ...

The results were further supported by data from continuous glucose monitoring (CGM; Freestyle Libre Pro iQ), which was used by approximately 80% of patients in the study and reported in a separate ...

Continuous glucose monitoring (FreeStyle Libre 2, Abbott Laboratories) was carried out across the study to assess the daily time spent in euglycemia (3.9-7.8 mmol/L) and provide markers of ...

Returns for ABT stock were 31% in 2021, -21% in 2022, and 2% in 2023, while for MDT stock ... seeing double-digit growth lately, led by FreeStyle Libre. The nutritional segment is benefiting ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per ...

again accusing Abbott of patent infringement for its FreeStyle Libre 2 device. This sparked a flurry of litigation between the parties in the US. Since 2021, Abbott and DexCom have been involved ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.